Haemonetics Corp Mass Stock Price, News & Analysis

Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2023 financial results on February 7, 2023, at 6:00 AM ET. A conference call for investors and analysts will follow at 8:00 AM ET on the same day, allowing participants to discuss the results and ask questions. Registration is required to access the call, and a live webcast will also be available on the company's investor relations website. A replay of the call will be accessible for one year post the event.

Haemonetics Corporation (NYSE: HAE) announced that President and CEO Chris Simon will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023, at 2:15 PM Pacific time. The live presentation will be available via audio webcast, accessible through Haemonetics' Investor Relations website. A replay will be available for 30 days after the event. Haemonetics focuses on innovative medical solutions aimed at improving patient care and reducing healthcare costs, specifically in blood and plasma component collection.

Haemonetics Corporation (NYSE: HAE) announced that its financial results for the second quarter of fiscal 2023, ending October 1, 2022, are now available on its Investor Relations website. A conference call and webcast will occur at 8:00 a.m. ET on November 7, 2022, to discuss these results. Interested parties can access the earnings release and supplemental information via provided links. A replay will be available for one year after the conference call. Haemonetics focuses on innovative medical products for improving patient care and reducing healthcare costs.

Haemonetics Corporation (NYSE: HAE) announced plans to release its second quarter fiscal year 2023 financial results on November 7, 2022, at 6:00 am ET. An accompanying conference call will be held at 8:00 am ET the same day for investors and analysts to discuss the results. Participants can access the call via teleconference or live webcast on Haemonetics' investor relations website. A replay of the call will be available for one year starting at 11:00 am ET on November 7, 2022.

Haemonetics Corporation (NYSE: HAE) has appointed Roy Galvin as the President of Global Plasma and Blood Center, effective October 10, 2022. Galvin brings over 25 years of experience from Medtronic, where he held various senior roles. He aims to drive transformational growth and enhance leadership in plasma collection and donor management solutions. His appointment comes at a crucial time as the company seeks to meet the rising global demand for plasma-derived therapies and improve productivity and cost efficiency in collection processes.

Haemonetics Corporation (NYSE: HAE) announced it has received CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous closure systems. This certification enables the company to launch these products in the European Union and other regions recognizing CE marking. The VASCADE system is tailored for small-bore femoral closure in various medical procedures, while VASCADE MVP is designed for mid-bore closures, particularly after cardiac ablation. Both systems aim to improve patient outcomes and hospital efficiency.

Haemonetics Corporation (NYSE: HAE) announced on August 29, 2022, a partnership with Epic, a major Electronic Health Record (EHR) provider, to integrate its SafeTrace Tx® blood bank information system into Epic's hospital network. SafeTrace Tx enhances transfusion management by ensuring patient safety and operational efficiency through comprehensive data management. This agreement aims to improve hospital transfusion processes amid ongoing staffing and blood supply challenges. Haemonetics continues to focus on innovative solutions to enhance patient care and optimize hospital operations.

Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET. Investors can access the live presentation via a webcast, with a replay available for 180 days post-event, starting at 12:00 p.m. ET. Haemonetics focuses on innovative medical products to enhance patient care and improve healthcare costs.

Haemonetics Corporation (NYSE: HAE) released its financial results for Q1 FY23, ending July 2, 2022. The results and additional analytical information are available on the company's Investor Relations website. A conference call is scheduled for August 10, 2022, at 8:00 a.m. EDT to discuss these results with investors and analysts. Participants can access the call via a teleconference link or live webcast. Earnings release and supplemental documents related to the quarter were also posted online for detailed review.